Source comparison
Follistatin-344 vs Sermorelin: Research Peptide Comparison
This table contrasts the core research characteristics, mechanisms, and practical considerations for follistatin-344 and Sermorelin across key parameters. Primary Mechanism Binds and sequesters myostatin and activin to prevent ActRIIB receptor activation and m
This comparison does not assign a generated winner or score.
- This table contrasts the core research characteristics, mechanisms, and practical considerations for follistatin-344 and Sermorelin across key parameters.
- Primary Mechanism
- Binds and sequesters myostatin and activin to prevent ActRIIB receptor activation and muscle growth suppression
- Stimulates GHRH receptors on pituitary somatotrophs, triggering cAMP-mediated GH secretion
- Follistatin removes genetic muscle brakes locally; Sermorelin amplifies systemic GH pulses
- Half-Life
- Approximately 3 hours in circulation
- 8–12 minutes in plasma
- Follistatin allows once-daily dosing; Sermorelin requires timing around endogenous GH peaks
- Molecular Weight
- 37.8 kDa (glycoprotein)
- 3.36 kDa (peptide)
- Larger size gives follistatin greater stability; smaller Sermorelin degrades faster
- Research Dosing Range
- 50–200mcg localized; 1–5mg/kg systemic (animal models)
- 100–500mcg subcutaneous (human-equivalent models)
- Dosing reflects mechanism. Follistatin used at injection site, Sermorelin systemic
- Post-Reconstitution Stability
- 28 days at 2–8°C with <10% degradation
- 7 days at 2–8°C with 40–50% degradation
- Follistatin suits long-term studies; Sermorelin demands frequent fresh preparation
- Tissue Specificity
- Acts locally at sites of myostatin/activin expression or administration
- Systemic. Effects mediated through hepatic IGF-1 production after GH release
- Follistatin for localized hypertrophy/fibrosis; Sermorelin for whole-body metabolic studies
- Regulatory Pathway
- TGF-beta superfamily antagonism (myostatin, activin, GDF-11)
- Hypothalamic-pituitary-IGF-1 axis stimulation
- Follistatin bypasses hormonal feedback; Sermorelin requires intact endocrine function
- Primary Research Applications
- Muscle hypertrophy mechanisms, muscular dystrophy models, fibrosis reduction (liver, heart)
- GH deficiency restoration, body composition studies, sleep architecture, aging research